Highlights IO Biotech, Inc.

Equities

IOBT

US4497781090

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-29 pm EDT			5-day change	1st Jan Change
1.23 ^USD	-4.65%		-7.52%	-34.57%

May. 15	HC Wainwright Adjusts IO Biotech Price Target to $12 From $8, Maintains Buy Rating	MT
May. 14	IO Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IO Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
IO Biotech, Inc. Presents New Data At Aacr 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, Io102-Io103	Apr. 09	CI
IO Biotech Announces Acceptance of Abstract to Be Presented at the 2024 American Association for Cancer Research Annual Meeting	Mar. 06	CI
IO Biotech, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 05	CI
IO Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial	Dec. 21	CI
IO Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma	Nov. 10	CI
IO Biotech, Inc. Announces Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology Congress	23-10-23	CI
IO Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial At University of California Davis Comprehensive Cancer Center	23-07-28	CI
IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone	23-06-14	CI
IO Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
IO BIOTECH, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-14	AQ
IO Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14	CI
IO Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14	CI
IO Biotech : March 2023 Investor Deck	23-03-14	PU
IO Biotech : Investor Deck	23-01-09	PU
IO Biotech : Investor Deck	22-11-11	PU
IO BIOTECH, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-11-09	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights IO Biotech, Inc.

Equities

IOBT

US4497781090

Highlights

Filters